CommercialCoverageMedium impact
Diabetic Neuropathy: Selected Treatments (CPB 0729, reviewed 2026-10-21)
Aetna·Pain Management, Neurology, Neurosurgery +2 more·Medical Policy
We identified it
Oct 25, 2026
Summary
Aetna's CPB 0729 policy (reviewed 2026-10-21) establishes medical necessity criteria for diabetic neuropathy treatments, covering percutaneous electrical stimulation (limited to ≤4 weeks) and dorsal column stimulation (per CPB 0194 criteria), while classifying 30+ interventions as experimental/investigational—including acupuncture, stem cells, nerve blocks, surgical decompression, and topical ketamine. This is a restatement of established coverage policy with no stated effective date change; billing teams should verify current applicability and confirm whether their practice has implemented these coverage determinations.
Action Required
Already effective (policy reviewed 2026-10-21): Verify whether the practice has implemented Aetna's diabetic neuropathy coverage determinations in billing workflows. Specifically: (1) Billing team should confirm that claims for percutaneous electrical stimulation (CPT 64555, E0745) are limited to ≤4 weeks of treatment and that longer durations are denied per policy; (2) Verify that dorsal column stimulation claims (CPT 63650, 63655, 63685) require prior authorization and compliance with CPB 0194 criteria; (3) Confirm that experimental codes listed (e.g., acupuncture 97810–97814, nerve blocks 64400–64450, surgical decompression 64702–64726, and stem cell procedures 38232, 38241) are programmed to deny with denial reason referencing experimental/investigational status; (4) Update internal coverage checklists and claim submission templates to reflect these coverage restrictions. Contact Aetna directly if the practice is uncertain whether current applicability applies to all active Aetna commercial plans or specific plan variants.